Creative Medical Technology Holdings, Inc. (CELZ)
1.04
-0.04
(-3.70%)
USD |
NASDAQ |
Sep 09, 16:00
1.06
+0.02
(+1.92%)
After-Hours: 17:45
Creative Medical Technology Holdings Enterprise Value : -1.804M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -1.804M |
| September 04, 2026 | -1.609M |
| September 03, 2026 | -1.934M |
| September 02, 2026 | -1.479M |
| September 01, 2026 | -1.674M |
| August 31, 2026 | -1.479M |
| August 28, 2026 | -1.414M |
| August 27, 2026 | -1.414M |
| August 26, 2026 | -1.090M |
| August 25, 2026 | -0.7649M |
| August 24, 2026 | -0.9597M |
| August 21, 2026 | -0.3105M |
| August 20, 2026 | -0.5052M |
| August 19, 2026 | -1.544M |
| August 18, 2026 | -1.804M |
| August 17, 2026 | -1.674M |
| August 14, 2026 | -0.8948M |
| August 13, 2026 | -0.7649M |
| August 12, 2026 | -1.025M |
| August 11, 2026 | -0.7649M |
| August 10, 2026 | -1.025M |
| August 07, 2026 | 0.4036M |
| August 06, 2026 | -1.349M |
| August 05, 2026 | -4.473M |
| August 04, 2026 | -4.554M |
| Date | Value |
|---|---|
| August 03, 2026 | -4.568M |
| July 31, 2026 | -4.504M |
| July 30, 2026 | -3.853M |
| July 29, 2026 | -4.322M |
| July 28, 2026 | -4.034M |
| July 27, 2026 | -3.665M |
| July 24, 2026 | -3.555M |
| July 23, 2026 | -3.553M |
| July 22, 2026 | -3.354M |
| July 21, 2026 | -3.421M |
| July 20, 2026 | -3.212M |
| July 17, 2026 | -3.108M |
| July 16, 2026 | -3.232M |
| July 15, 2026 | -3.479M |
| July 14, 2026 | -3.347M |
| July 13, 2026 | -3.269M |
| July 10, 2026 | -2.894M |
| July 09, 2026 | -2.704M |
| July 08, 2026 | -2.323M |
| July 07, 2026 | -1.739M |
| July 06, 2026 | -1.349M |
| July 02, 2026 | -0.9597M |
| July 01, 2026 | -0.5702M |
| June 30, 2026 | 0.5984M |
| June 29, 2026 | -2.830M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.511M |
| Total Expenses (Quarterly) | 1.512M |
| EPS Diluted (Quarterly) | -0.4085 |
| Earnings Yield | -170.9% |
| Normalized Earnings Yield | -170.92 |